Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eribulin Mesylate and Atezolizumab in Urothelial Cancer
NCT03237780Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Jul 2018
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of eribulin in urothelial carcinoma (UC), sponsored by National Cancer Institute. Started Jul 2018; status: active, not recruiting.
02
Drugs
eribulin
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT03237780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03237780.